AstraZeneca signs potential $240M R&D deal with Alchemia

04/24/2013 | Genetic Engineering & Biotechnology News

Alchemia and AstraZeneca agreed to collaborate in the discovery and potential development of novel small molecules against multiple targets using the former's Diversity Scanning Array and Versatile Assembly on Stable Templates chemistry technology. AstraZeneca will pay Alchemia an undisclosed upfront fee, research funding, and as much as $240 million in milestone fees plus royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI